Search results
Results from the WOW.Com Content Network
Provigil was initially approved to treat excessive daytime sleepiness resulting from narcolepsy, and later approved the drug for further label indications. Cephalon allegedly promoted Provigil for a five-year period as a non-stimulant drug for the treatment of sleepiness, tiredness, decreased activity, lack of energy, and fatigue.
Pfizer [2] $2.3 billion Off-label promotion, kickbacks: Bextra, Geodon, Zyvox, Lyrica: False Claims Act, FDCA 2013 Johnson & Johnson [7] $2.2 billion Off-label promotion, kickbacks: Risperdal, Invega, Nesiritide: False Claims Act, FDCA 2012 Abbott Laboratories [8] $1.5 billion Off-label promotion Depakote: False Claims Act, FDCA 2009 Eli Lilly ...
E. W. Kemble's "Death's Laboratory" on the cover of Collier's (June 3, 1905). A patent medicine, also known as a proprietary medicine or a nostrum (from the Latin nostrum remedium, or "our remedy") is a commercial product advertised to consumers as an over-the-counter medicine, generally for a variety of ailments, without regard to its actual effectiveness or the potential for harmful side ...
The clinic also spent nearly $100,000 during that period on Provigil, a stimulant that is “55 times more expensive than the generic equivalent,” the report said. In 2019, investigators tried ...
Reverse payment patent settlements, also known as "pay-for-delay" agreements, [1] are a type of agreement that has been used to settle pharmaceutical patent infringement litigation (or threatened litigation), in which the company that has brought the suit agrees to pay the company it sued. That is, the patent holder pays the alleged infringer ...
Modafinil, sold under the brand name Provigil among others, is a central nervous system (CNS) stimulant and eugeroic (wakefulness promoter) medication used primarily to treat narcolepsy, [3] [8] [15] a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. [16]
Multiple attempts by USA TODAY to reach U.S. Immigration and Customs Enforcement by email and phone, at the agency's Washington, D.C.; South Florida and West Texas offices went unanswered.
The Court found contributory infringement for the sale of the defendant's ink with patent owners machine. Westinghouse Electric and Manufacturing Company v. Wagner Electric and Manufacturing Company. - Supreme Court, 1912. Bauer & Cie. v. O'Donnell - Supreme Court, 1913. Patent licensing terms do not include dictating the price of the product ...